MINIREVIEWS

Portal vein thrombosis in liver cirrhosis

Nao Kinjo, Hirofumi Kawanaka, Tomohiko Akahoshi, Yoshihiro Matsumoto, Masahiro Kamori, Yoshihiro Nagao, Naotaka Hashimoto, Hideo Uehara, Morimasa Tomikawa, Ken Shirabe, Yoshihiko Maehara

Nao Kinjo, Hirofumi Kawanaka, Tomohiko Akahoshi, Yoshihiro Matsumoto, Masahiro Kamori, Yoshihiro Nagao, Naotaka Hashimoto, Hideo Uehara, Morimasa Tomikawa, Ken Shirabe, Yoshihiko Maehara, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Nao Kinjo, Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
Author contributions: Kinjo N drafted the article; Matsumoto Y, Kamori M, Nagao Y, Hashimoto N and Uehara H contributed to the collection and assembly of manuscripts; Kawanaka H, Akahoshi T, Tomikawa M and Shirabe K participated in the critical revision of the article for important intellectual content; Maehara Y contributed to the final approval of the article.
Correspondence to: Nao Kinjo, MD, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Telephone: +81-92-6425466 Fax: +81-92-6425482 Received: November 11, 2013 Revised: December 22, 2013 Accepted: January 13, 2014 Published online: February 27, 2014

Abstract
Portal vein thrombosis (PVT) is considered to be a frequent complication of liver cirrhosis. However, unlike PVT in patients without cirrhosis, very few data are available on the natural history and management of PVT in cirrhosis, despite its association with potentially life-threatening conditions, such as gastroesophageal bleeding and acute intestinal ischemia. Moreover, no consensus regarding PVT in cirrhosis exists. The understanding of PVT in cirrhosis is incomplete. In addition, information on the management of PVT in cirrhosis is inadequate. The aims of this review are to: (1) assemble data on the physiopathological mechanism, clinical findings, diagnosis and management of PVT in cirrhosis; (2) describe the principal factors most frequently involved in PVT development; and (3) summarize the recent knowledge concerning diagnostic and therapeutic procedures.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Key words: Portal vein thrombosis; Liver cirrhosis; Thrombophilic factors; Anticoagulation; Splenectomy
Core tip: Portal vein thrombosis (PVT) is considered to be a frequent complication of liver cirrhosis; however, very few data are available on the natural history and management of PVT in cirrhosis, despite its association with potentially life-threatening conditions. The understanding and information on the management of PVT in cirrhosis are incomplete. The aims of this review are to: (1) assemble data on the physiopathological mechanism, clinical findings, diagnosis and management of PVT in cirrhosis; (2) describe the principal factors most frequently involved in PVT development; and (3) summarize the recent knowledge concerning diagnostic and therapeutic procedures.

INTRODUCTION
Portal vein thrombosis (PVT), an obstruction of the portal vein or its branches by a blood clot, is encountered in a variety of clinical settings, such as myeloproliferative disease, cirrhosis, cancer and infection. More patients with cirrhosis are being diagnosed with PVT be-
cause current imaging techniques allow for the detection of asymptomatic PVT during routine ultrasonographic examination. PVT has a variety of clinical presentations, from asymptomatic to life-threatening conditions such as gastroesophageal bleeding and acute intestinal ischemia[13]. Although liver transplantation has altered the prognosis of patients with cirrhosis, the presence of PVT can exclude a patient from a transplant listing or negatively impact post-transplantation survival[6].

It remains unclear whether PVT is a consequence of severe liver disease, a factor aggravating underlying liver disease, or both. PVT is considered to be a frequent complication of liver cirrhosis; however, unlike PVT in patients without cirrhosis, very few data are available on its natural course and management despite its association with potentially life-threatening conditions. In addition, no consensus regarding PVT with cirrhosis exists. There is a growing need for optimal, evidence-based management of PVT in cirrhosis.

The aims of this review are to: (1) assemble evidence regarding the physiopathological mechanism, clinical findings, diagnosis and management of PVT in cirrhosis; (2) describe the principal factors most frequently involved in PVT development; and (3) summarize the most recent knowledge concerning diagnostic and therapeutic procedures.

DEFINITION OF ACUTE AND CHRONIC PVT

From a clinical point of view, PVT comprises two different entities: acute PVT and chronic PVT. Each represents a successive stage of the same disease. Although they share similar causes, they differ with respect to their management[9].

Acute PVT is characterized by the sudden formation of a thrombus within the portal vein[8]. The thrombus can involve variable portions of the mesenteric veins and/or splenic vein. Occlusion can be complete or partial, leaving a peripheral circulating channel.

In patients with chronic PVT, also known as portal cavernoma, the obstructed portal vein is replaced by a network of hepaticolar collateral veins connecting the patent portion of the vein upstream of the thrombus to the patent portion downstream. The number, size and location of these collaterals are extremely variable from patient to patient[8].

However, in patients with cirrhosis, it may be difficult to establish the “age” of the thrombosis because the criteria commonly used in patients without cirrhosis to define acute or chronic PVT (presence of collateral circulation and signs of portal hypertension) are already features of liver disease[7,8].

PREVALENCE

The prevalence of PVT in patients with cirrhosis has been reported more frequently in recent years. The reported prevalence of PVT is in the range of 0.6%-15.8% in patients with liver cirrhosis or portal hypertension[4-6]. The presence of PVT is reportedly 0.6% when evaluated by angiographic studies[7], 4.4% when evaluated by ultrasound[8], and 10%-12% when evaluated by computed tomography and magnetic resonance imaging[9,10]. Moreover, the prevalence of PVT increases with patient age and liver disease severity, reaching 15% in patients awaiting liver transplantation[11,12].

The etiology of liver disease influenced the prevalence of PVT in a study of 885 patients who underwent liver transplantation. The prevalence of PVT was 3.6% in primary sclerosing cholangitis, 8% in primary biliary cirrhosis, 16% in alcoholic and hepatitis B virus-related cirrhosis, and 35% in hepatocellular carcinoma (HCC)[13].

ETIOLOGY OF PVT IN CIRRHOSIS

Inherited and acquired thrombophilic disorders, bacterial infection[16,17] and sluggish portal flow[18-20] may all play a role in the high prevalence of PVT in patients with cirrhosis.

Cirrhosis was recently considered to be a hypercoagulable state, not a hypocoagulable state. The levels of both pro- and anti-coagulation proteins are reduced under conditions of hepatic synthetic impairment in patients with liver cirrhosis. Coagulation and anticoagulation mechanisms remain balanced but are carried out at a lower level[20-22]. The net result is a hemostatic balance that is compensated under normal circumstances, with no tendency for bleeding or thrombosis[22]. In cirrhosis, however, this equilibrium can easily tilt towards either bleeding or thrombosis[19,23-28]. Some authors have demonstrated that elevated levels of factor V (a procoagulant driver) in combination with decreased levels of protein C (an anti-coagulant driver), both of which are typically found in patients with cirrhosis (i.e., procoagulant imbalance), are probably related to partial resistance to the in vitro anticoagulant action of thrombomodulin[27-30]. However, in patients with impaired synthetic function and low plasma levels of natural coagulation inhibitors, there is currently no simple way to ascribe such a low level to a pre-existing deficiency[29].

A thrombophilic genotype, including factor V Leiden G1691A mutation[32,33], methylenetetrahydrofolate reductase (TT677) mutation[34,35], and prothrombin (G20210A)[36,37], is associated with the formation of PVT. However, they may play a minor pathogenic role in the formation of PVT.

Reduced portal flow velocity seems to be the most important predictive variable for PVT development in patients with cirrhosis[37-39]. Amitrano et al[39] suggested that portal blood stasis in patients with cirrhosis is the main change favoring thrombosis, even in the presence of other local, systemic, congenital and acquired factors. Kinjo et al[40] performed Doppler ultrasonographic examinations after splenectomy in patients with cirrhosis and showed that portal venous flow was dramatically decreased by 49.2% in the PVT group but only by 6.6% in
the non-PVT group.

Splenectomy has recently been reported to play a role in the surgical strategy for HCC and interferon-based therapy for hepatitis C\(^{[40-43]}\). In addition, it can improve the prognosis for patients with cirrhosis by allowing them to receive interferon therapy or undergo treatment for HCC\(^{[44,45]}\). Despite the good results demonstrated in these studies, the high prevalence of PVT after splenectomy in patients with cirrhosis remains problematic\(^{[39,46]}\). It has been suggested that blood turbulence or stasis in the stump of the splenic vein after splenectomy might result in increased coagulability, leading to the propagation of splenic venous thrombus formation in the portal system after splenectomy\(^{[47]}\). Splenomegaly and a large splenic vein diameter are independent risk factors for PVT after splenectomy in patients with concomitant cirrhosis and portal hypertension\(^{[39,40,47]}\).

The role of sclerotherapy as a potential trigger for PVT is controversial\(^{[48,49]}\). Some recent reports showed that thrombopoietin receptor agonists might be associated with an increased incidence of PVT in patients with cirrhosis\(^{[50,51]}\).

**CLINICAL FINDINGS**

Clinical findings of PVT in cirrhosis vary from asymptomatic to life-threatening conditions. Partial PVT, which is now often detected by routine ultrasonography or computed tomography, might be associated with few symptoms. However, complete PVT may present as abdominal or lumbar pain with sudden onset or progression over a few days. Rapid, complete obstruction of the portal vein or mesenteric veins without involvement of the mesenteric venous arches induces intestinal congestion, which manifests as severe, continuous, colicky abdominal pain and occasionally as nonbloody diarrhea\(^{[1-3]}\). The bleeding risk appears to be higher in patients with PVT and cirrhosis than in patients with cirrhosis alone (39% vs 27%, respectively)\(^{[52]}\). In many patients, however, the thrombus is partial and its aspects and location change in follow-up images. Laboratory findings, including the levels of aminotransaminase, fibrin and fibrinogen degradation products, and d-dimers, are often normal in many cases of developing PVT.

Chronic PVT is commonly diagnosed after a fortuitous finding of hypersplenism or portal hypertension. In the majority of patients it is asymptomatic. Gastrointestinal bleeding is better tolerated by patients with chronic PVT than in those with other forms of portal hypertension, probably because patients with PVT are usually younger and have no liver dysfunction. The occurrence of ascites or encephalopathy in patients with chronic PVT is uncommon and is usually encountered only transiently following gastrointestinal bleeding or when unrelated renal failure or marked sepsis is present in older patients\(^{[5]}\). Liver test results are typically normal in patients with portal cavernoma in the absence of underlying liver disease. Biliary symptoms related to portal cholangiopathy (jaundice, biliary pain, cholangitis, cholecystitis or pancreatitis) rarely reveal the presence of a cavernoma\(^{[53,54]}\). Hepatopulmonary syndrome is present in about 10% of patients.

**DIAGNOSIS**

More of these patients are being diagnosed with PVT because current imaging techniques allow for the detection of asymptomatic PVT during routine ultrasonography in patients with cirrhosis.

Ultrasound and Doppler ultrasound are almost always sufficient for a diagnosis of PVT\(^{[35,55]}\). In most patients, the diagnosis of acute PVT can be rapidly established using noninvasive imaging. Ultrasound sonography can show hyperechoic material in the portal lumen with distension of the portal vein and its tributaries. Doppler imaging shows the absence of flow in part or all of the lumen.

Enhanced computed tomography (CT) can show a lack of luminal enhancement in the portal vein, increased hepatic enhancement in the arterial phase, and decreased hepatic enhancement in the portal phase\(^{[56]}.\) CT and magnetic resonance (MR) angiography are more sensitive techniques than Doppler imaging with respect to assessment of the extent of the thrombus within the portal venous system\(^{[56-58]}\). Definitive diagnosis of PVT can be obtained by MR imaging (MRI) and CT; the former provides a better evaluation of the extent of the thrombosis, particularly in the mesenteric vein, reaching a sensitivity and specificity of 98%-100%. CT provides information not only about the extent of the thrombosis and the development of collateral circulation, but also about the state of the abdominal organs. It is the procedure of choice when intestinal ischemia or hepatocellular carcinoma is suspected\(^{[59,60]}\). A diagnosis of cavernoma is readily achieved by abdominal imaging with ultrasound, CT or MRI, which shows serpiginous structures while the main portal vein and/or its main branches are not visible.

A recent study showed that positive intrathrombus enhancement on contrast-enhanced sonograms is an accurate predictor of recanalization in patients with recent portal thrombosis\(^{[61]}\).

**TREATMENT**

Optimal management of PVT in cirrhosis is not addressed in any current consensus publication. There are a few reports about the factors that influence recanalization or the extent of thrombosis; however, the actual impact of PVT treatment on the natural course of cirrhosis has not been investigated. No randomized controlled trials have been performed and most existing evidence concerning PVT treatment is based on case series and is of low quality.

PVT increases the risk of variceal bleeding and is reportedly an independent risk factor for the inability to
control variceal bleeding. In addition, PVT can be a life-threatening emergency when it extends to the superior mesenteric vein, leading to intestinal infarction. Anticoagulated patients with cirrhosis have better recanalization rates and PVT extension than non-anticoagulated patients. Therefore, in patients with concomitant cirrhosis and PVT, a treatment algorithm that includes anticoagulation and transjugular intrahepatic portosystemic shunting (TIPS) provides a good chance of complete repermeation, reduces portal hypertensive complications and decreases the rate of thrombosis progression.

Francoz et al. evaluated patients with cirrhosis awaiting liver transplantation and found that survival was significantly lower in those with complete PVT at the time of surgery ($P = 0.04$). Furthermore, the rate of partial or complete recanalization was significantly higher among patients receiving anticoagulation therapy than among those not receiving anticoagulation therapy ($P = 0.002$).

Conversely, some reports have shown that PVT has little influence on prognosis in patients with cirrhosis. Maruyama et al. evaluated 150 patients with virus-related cirrhosis but without PVT at baseline; PVT developed in 28% of patients (42/150), with a cumulative incidence of 12.8%, 20% and 38.7% at 1, 5 and 8-10 years, respectively. The natural course of thrombosis was improvement in 47.6% of patients, unchanged in 45.2%, and worsened in 7.2%. Spontaneous resolution or an unchanged appearance was the most common outcome of PVT; therefore, cirrhotic PVT had little influence on prognosis. In their multivariate analysis, Luca et al. noted that there was no clear association between progression or regression of partial PVT and clinical outcome and that the Child-Pugh score at the time of diagnosis was the only independent predictor of survival.

In the field of liver transplantation, there is accumulating evidence that PVT, especially thrombus extension to the superior mesenteric vein, may adversely affect the outcome of transplantation. Thus, patients with concomitant cirrhosis and PVT who are on the waiting list for liver transplantation should be treated with anticoagulation therapy. PVT prior to liver transplantation is an independent prognostic factor for post-transplant survival and complete or partial PV recanalization has been associated with a better survival rate after liver transplantation. It has also been shown that individuals with PVT at the time of liver transplantation are at higher risk of recurrent PVT after transplantation and of requiring retransplantation. The increased mortality and morbidity rates associated with PVT are mostly restricted to the first year after liver transplantation and actuarial survival after 1 year is good. Therefore, PVT cannot be considered to be a contraindication to liver transplantation.

Anticoagulation therapy is of proven benefit in patients with acute deep vein thrombosis. The optimal anticoagulation regimen for the treatment and monitoring of PVT has not yet been fully explored and no clear recommendations exist regarding this issue in recent guidelines or consensus publications. Treatment strategies most often include the use of anticoagulation, while thrombectomy and TIPS are considered second-line options.

The goal of anticoagulation therapy for acute PVT is to recanalize the obstructed veins, which will prevent intestinal infarction and portal hypertension. Correction of the causal factors should be achieved as soon as possible.

Vitamin K antagonists (VKA) have been used in some studies to treat PVT in patients with cirrhosis. The rate of PV recanalization in patients with cirrhosis treated with VKA is about 40%. Orally administered VKA is more acceptable to patients; however, treatment with VKA is particularly difficult in patients with cirrhosis, mostly because anticoagulation monitoring is complex in this particular situation. Notably, international normalized ratio (INR) monitoring in patients with liver disease probably overestimates the bleeding risk because this international sensitivity index is determined using plasma from patients taking VKA. The INR has only been validated in individuals with normal liver function on stable anticoagulation. A 29% variation in the mean INR was reported in patients with cirrhosis in a study in which three different thromboplastin reagents were used. It is also unclear whether a target INR between 2 and 3 is adequate in individuals with an abnormal INR before anticoagulation therapy.

No consensus exists regarding the optimal duration of anticoagulation therapy in these settings. Complete recanalization can be delayed until the sixth month of anticoagulation therapy. However, whether this is also true for patients with cirrhosis who develop acute PVT remains to be determined.

Randomized controlled trials of anticoagulation therapy for the prevention of recurrent thrombosis are lacking in cirrhotic PVT. In patients with deep vein thrombosis, a lack of complete recanalization indicates a high risk of recurrence after cessation of anticoagulation therapy.

The frequent association with permanent prothrombotic disorders and the risk of intestinal infarction support the use of anticoagulation. However, an increased risk of bleeding secondary to portal hypertension raises concerns. Delgado et al. reported that re-thrombosis after complete recanalization occurred in 38.5% of patients with cirrhosis after anticoagulation therapy was stopped. Thatipelli et al. stated that prolonged anticoagulant therapy does not appear to be justified based on the low rate of recurrence and substantial rate of major hemorrhage. To avoid the extension of thrombosis to the splanchnic vessels, prophylactic anticoagulation should be continued in patients with underlying thrombophilic conditions or in patients who are likely candidates for future liver transplantation.

The choice of the anticoagulation regimen must also account for the potential need to reverse the effect of anticoagulation. There is no current consensus or guideline on whether nonselective beta blockers, endoscopic
variceal ligation or combination therapy is better for variceal bleeding prophylaxis.[69]

An attractive alternative to oral anticoagulants could be the use of low-molecular-weight heparin (LMWH), the dosing of which is weight based and thus does not necessitate screening. A 50%-80% portal vein recanalization rate was recently reported with the use of LMWH in 38 patients with cirrhosis, with only a few episodes of non-severe variceal bleeding.[62,63] Villa et al.[63] performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a LMWH, in preventing PVT in patients with advanced cirrhosis. They demonstrated that the actuarial probability of PVT was lower in the enoxaparin group (P = 0.006). The actuarial probability of survival was higher in the enoxaparin group (P = 0.020). No relevant side effects or hemorrhagic events were observed in their study. Enoxaparin appeared to delay the occurrence of hepatic decompensation and improve survival. However, an increased volume of distribution, such as that produced by ascites and edema, in patients with cirrhosis makes it difficult to determine the optimal dose of LMWH.[62]

The administration of antithrombin III (AT-III) could be an attractive alternative to PVT in cirrhosis. Kawanaka et al.[83] demonstrated that the low AT-III activity and further decreases in this activity are associated with PVT after splenectomy in patients with cirrhosis and that treatment with AT-III concentrates is likely to prevent the development of PVT in these patients.

TIPS and anticoagulation therapy are considered to be optimal treatment choices for PVT in cirrhosis.[84] TIPS completely recanalized the portal venous system in 57% of patients with cirrhosis and resulted in a marked decrease in 30% without major procedure-related complications. Despite problems associated with patency (bare stents, 38% in 12 mo and 85% in 24 mo; covered stents, 21% in 12 mo and 29% in 24 mo) and encephalopathy (27% at 12 mo, 32% at 24 mo), the long-term outcome of TIPS placement for cirrhotic PVT is excellent.[82] In addition, PVT prior to liver transplantation is an independent prognostic factor for post-transplant survival and TIPS prevents total portal vein occlusion in liver transplantation candidates with partial PVT.[83]

In patients with both cirrhosis and chronic PVT, there is no consensus on the indication for anticoagulant therapy. As described in the consensus for PVT in patients without cirrhosis, therapy for chronic PVT can be separated into prevention and treatment of gastrointestinal bleeding, prevention of recurrent thrombosis and treatment of portal cholangiopathy. When PVT is longstanding and cavernous transformation has occurred in the portal vein, prophylactic anticoagulation is reversed only in patients with thrombophilic conditions and/or a high risk of thrombus extension into the superior mesenteric vein. There is still sufficient evidence in favor of interventional therapy such as TIPS.[83] Data on endoscopic ligation are lacking in adult patients with chronic PVT.

CONCLUSION

PVT is a common problem in patients with cirrhosis, mostly in individuals with advanced liver disease. However, many known pathophysiological aspects of PVT and unresolved issues encountered in everyday practice remain to be addressed. The most optimal, most efficient and safest modalities for treatment, screening and monitoring must be established in future controlled trials.

REFERENCES

1. Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. Am J Med 1992; 92: 173-182 [PMID: 1543202 DOI: 10.1016/0002-9343(92)90109-O]
2. Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, Chapuleau RA, van Hattum J, Veggiaar FP, Hansen BE, Rosendaal FR, van Hoek B. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001; 49: 720-724 [PMID: 11680478 DOI: 10.1136/gut.49.5.720]
3. Condor B, Pessinone F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, Hadengue A, Erlinger S, Valla D. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490-497 [PMID: 11139889 DOI: 10.1053/gast.2001.21239]
4. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condor B, Denninger MH, Sauvanet A, Valla D, Durand F. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-697 [PMID: 15831918 DOI: 10.1136/gut.2004.042796]
5. Condor B, Pessinone F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32: 466-470 [PMID: 10960436]
6. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729-1764 [PMID: 19399912 DOI: 10.1002/hep.22772]
7. Tschatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31: 366-374 [PMID: 19863496 DOI: 10.1111/j.1365-2036.2009.04182.x]
8. Amitrano L, Guardascione MA. Management of portal vein thrombosis in cirrhotic patients. Mediterr J Hematol Infect Dis 2009; 1: e2009014 [PMID: 2141954 DOI: 10.4084/MJHID.2009.014]
9. Okuda K, Oishi K, Kimura K, Matsutani S, Sumida M, Goto N, Musha H, Takashi M, Suzuki N, Shinagawa T. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89: 279-286 [PMID: 4007419]
10. Gaiani S, Bolondi L, Li Bassi S, Zironi G, Siringo S, Barbara L. Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopic correlation in 228 patients. Gastroenterology 1991; 100: 160-167 [PMID: 1983617]
11. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, Balzano A. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-741 [PMID: 15094219 DOI: 10.1016/j.jhep.2004.01.001]
12. Nonami T, Yokoyama I, Iwasaki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology 1992; 16: 1195-1198 [PMID: 1427658 DOI: 10.1002/hep.1840160515]
13. Verdel MA, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J, Mayer D, McMaster P, Pirenne J. Portal vein thrombosis in adults undergoing liver transplantation risk factors, screening, management, and outcome. Transplantation 2000;
anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? Gut 2000; 46: 534-539 [PMID: 10766684]

32. Janssen HL, Meinardi JR, Vleggar FP, van Uhm SH, Haagse- ma EB, van Der Meer FJ, van Hattum J, Chameleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96: 2364-2368 [PMID: 11018844]

33. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800 [PMID: 9243536]

34. Pasta L, Marrone C, D’Amico M, Virdone R, D’amico G, Sammarco P, Fabiano C, Pagliaro L. MTHFR C677T mutations in liver cirrhosis with and without portal vein thrombosis. Liver Int 2006; 26: 269-270 [PMID: 16448467]

35. Gabr MA, Bessa SS, El-Zamarni EA. Portal vein thrombosis in Egyptian patients with liver cirrhosis: Role of methylene-tetrahydrofolate reductase C677T gene mutation. Hepatol Res 2010; 40: 486-493 [PMID: 20374299 DOI: 10.1111/j.1872-034X.2010.00628.x]

36. Amitrano L, Guaridascione MA, Ames PR, Margaglione M, Iannaccone L, Liscicchio V, Marmo R, Ames PR, Balzano A. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-348 [PMID: 10655256 DOI: 10.1002/hep.10182]

37. Manuccion PM. Abnormal hemostasis tests and bleeding in chronic liver disease: An update of a clinical significance. J Clin Gastroenterol 2005; 39: 727-733 [PMID: 15736874]

38. Ben-Ari Z, Osnat E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94: 2977-2982 [PMID: 10520855]

39. Erkan O, Bozdag AM, Disibeyaz S, Olgaz D, Ozcan M, Bahar K, Karayalin S, Ozden A, Bozkaya H, Yurdacikin D, Zunalmoglu O. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-343 [PMID: 15716659]

40. Tripodi A, Primignani M, Lemm L, Chantarangkul V, Manuccion PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013; 59: 265-270 [PMID: 23832372 DOI: 10.1016/j.jhep.2013.03.036]

41. Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008; 47: 1384-1393 [PMID: 18318436 DOI: 10.1002/hep.22192]

42. Delaheusse B, Labat-Debleixe V, Decalonne L, d’Alterloche L, Perennou JM, Gruel Y. Comparative study of coagulation and thrombin generation in the portal and jugular plasma of patients with cirrhosis. Thromb Haemost 2010; 104: 741-749 [PMID: 20860160 DOI: 10.1160/TH10-01-0040]

43. Tripodi A, Ansee QM, Sogard KR, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9: 1713-1723 [PMID: 21729237 DOI: 10.1111/j.1538-7836.2011.04429.x]

44. Fishel NC, Wilde JT, Roper J, Elias E. Deficiency of natural
Res 2009, 39: 439-447 [PMID: 19207381 DOI: 10.1111/j.1872-034X.2008.00481.x]
46 Yoshida M, Watanabe Y, Horiiuchi A, Yamamoto Y, Sugishita T, Kawachi K. Portal and splenic venous thrombosis after portal vein embolization in patients with hypersplenism. Hepatogastroenterology 2009; 56: 538-541 [PMID: 19579638]
47 Winslow ER, Brunt LM, Drehin JA, Soper NJ, Klingensmith ME. Portal vein thrombosis after splenectomy. Am J Surg 2002; 184: 631-635; discussion 633-636 [PMID: 12488196]
48 Amirano L, Brancaccio V, Guardascione MA, Margaglione M, Sacco M, Martino R, De Nutti C, Mosca S, Iannaccone L, Ames PR, Romano L, Balzano A. Portal vein thrombosis after variceal sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002; 34: 535-538 [PMID: 12170404]
49 Polistoske D, Ralls P, Korula J. Portal vein thrombosis following endoscopic variceal sclerotherapy. Prospective controlled comparison in patients with cirrhosis. Dig Dis Sci 1996; 41: 185-190 [PMID: 8656755]
50 Adhul NH, Giannini EG, Tayyab G, Molins A, Lee JW, Andruliti A, Jeffers L, McHutchison J, Chen P, Han KH, Campbell B, Hyde D, Brainsky A, Theodore D. Elltrombopag after procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367: 716-724 [PMID: 22913681 DOI: 10.1056/NEJMoa1110709]
51 Dultz G, Kronenberger B, Azizi A, Mihm U, Vogl TJ, Sarrazin U, Sarrazin C, Zeuzem S, Hofmann WP. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011; 55: 229-232 [PMID: 21310200 DOI: 10.1016/j.jhep.2011.01.020]
52 North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first varical hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988; 319: 983-989 [PMID: 3262230 DOI: 10.1056/NEJM198810313191905]
53 Condat B, Vilgrain V, Asselah T, O'Toole D, Rufat P, Zappa AM, Clavien PA. Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR venography study. J Hepatol 2003; 37: 1302-1308 [PMID: 12774008 DOI: 10.1053/j.hep.2003.50232]
54 Khuroo MS, Dar MY, Yattoo GN, Khan BA, Boda MI, Zargar SA, Javid G, Allar MS. Serial cholangiographic appearances in recurrent pyogenic cholangitis. Gastrointest Endosc 1993; 39: 674-679 [PMID: 8224691 DOI: 10.1016/0016-5107(93)90221-7]
55 Subramanyan JP, Barthalaz EJ, Lefleur RS, Horii SC, Hulnick DH. Portal venous thrombosis: correlation analysis of sonography, CT and angiography. Am J Gastroenterol 1984; 79: 773-776 [PMID: 638690]
56 Ueno N, Sasaki A, Tomiyama T, Tano S, Kimura K. Color Doppler ultrasonography in the diagnosis of cavernous transformation of the portal vein. J Clin Ultrason 1997; 25: 223-227 [PMID: 9314103]
57 Bach AM, Hahn LE, Brown KT, Gettrandman GL, Herman SK, Fong Y, Blumgart LH. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1998; 201: 149-154 [PMID: 8816536]
58 Chou CK, Mak CW, Tzeng WS, Chang JM. CT of small bowel ischemia. Abdom Imaging 2004; 29: 18-22 [PMID: 15160748 DOI: 10.1007/s00261-003-0073-3]
59 Lee HK, Park SJ, Yi BH, Yeon EK, Kim JH, Hong HS. Portal vein thrombosis: CT features. Abdom Imaging 2008; 33: 72-79 [PMID: 17694406 DOI: 10.1007/s00261-007-9290-x]
60 Tublin MF, Dodd GD, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997; 168: 719-723 [PMID: 9057522 DOI: 10.2214/ajr.168.5.9057522]
61 Maruyama H, Ishibashi H, Takahashi M, Shimada T, Kamesaki H, Yokosuka O. Prediction of the therapeutic effects of anticoagulation for recent portal vein thrombosis: a novel approach with contrast-enhanced ultrasound. Abdom Imaging 2012; 37: 431-438 [PMID: 21904887 DOI: 10.1007/s00261-011-0795-9]
62 Amirano L, Guardascione MA, Menichese A, Martinoto R, Scaglioni M, Govine S, Romano L, Balzano A. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44: 448-451 [PMID: 19730112 DOI: 10.1097/MCG.0b013e3181b3a44]
63 Zengolo M, Sartori T, Rossetto V, Burra P, Cillo U, Bocagini P, Gasparini D, Miotto D, Simioni P, Tschatsch E, A Burroughs K. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012, 32: 919-927 [PMID: 22438584 DOI: 10.1111/j.1478-3231.2012.02785.x]
64 Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol 2013; 108: 568-574 [PMID: 23381015 DOI: 10.1038/ajg.2012.452]
65 Perujo G, Cesarus M, Milazzo M, Marrone G, Mamone G, Cino F, Maruzzelli L, Miraglia R, Floridia G, Vizzini G. Natural course of extraportal nonmalignant portal vein thrombosis in patients with cirrhosis. Radiology 2012; 265: 124-132 [PMID: 22891357]
66 Lendore J, Raffin G, Cojas N, Duek F, Barros Schelotto P, Trigo P, Quarín C, Garay V, Inventarco. Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HPB (Oxford) 2007; 9: 352-356 [PMID: 18345318 DOI: 10.1016/j.hpb.2007.05.035]
67 Selvaggi G, Weppler D, Nishiwa S, Moon J, Levi D, Kato T, Tzakis AG. Ten-year experience in porto-caval hemi transplantation for liver transplantation in the presence of portal vein thrombosis. Am J Transplant 2007; 7: 454-460 [PMID: 17229075]
68 Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, Lynch RJ, Marrero JA, Pelletier SJ. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl 2010, 16: 83-90 [PMID: 20035521 DOI: 10.1002/lt.21941]
69 Rodríguez-Castro KI, Porto RJ, Nadal E, Germaini G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation 2012; 94: 1145-1153 [PMID: 23128996 DOI: 10.1097/TP.0b013e318266e953]
70 Doenecke A, Tsui TY, Zuelke C, Scherer MN, Schnitzbauer AA, Schlitt HJ, Obed A. Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity. Clin Transplant 2010; 24: 48-55 [PMID: 1926435 DOI: 10.1111/j.1399-069X.2009.00977.x]
fraction. Br J Surg 1990; 77: 601-603 [PMID: 2200547]

77 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 4545-5455 [PMID: 18574272 DOI: 10.1378/chest.08-0658]

78 Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010; 8: 200-205 [PMID: 19782767 DOI: 10.1016/j.cgh.2009.09.019]

79 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156 [PMID: 21751907 DOI: 10.1056/NEJMra1011170]

80 Senzolo M, Ferronato C, Burra P, Sartori MT. Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. Intern Emerg Med 2009; 4: 161-162; author reply 163-164 [PMID: 19130177 DOI: 10.1007/s11739-008-0219-y]

81 Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colapi S, Tata C, Zecchini R, Gatto S, Petta S, Lei B, Bernabucci V, Vuotico R, De Maria N, Schepis F, Karampatou A, Caporalì C, Simonì L, Del Buono M, Zambotto B, Turolla E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-1260.e1-4 [PMID: 22819864 DOI: 10.1053/j.gastro.2012.07.018]

82 Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75-82 [PMID: 20958919 DOI: 10.1111/j.1478-3275.2010.02358.x]

83 Kawanaka H, Akahoshi T, Kinjo N, Konishi K, Yoshida D, Anegawa G, Yamaguchi S, Uehara H, Hashimoto N, Tsutsumi N, Tomikawa M, Maehara Y. Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. Ann Surg 2010; 251: 76-83 [PMID: 19864937 DOI: 10.1097/SLA.0b013e3181b8dad]

84 Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012; 57: 203-212 [PMID: 22446990 DOI: 10.1016/j.jhep.2011.12.034]

85 Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzi L, Vizzini G, Tuzzolino F, Gridelli B, Bosch J. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011; 60: 846-852 [PMID: 21357252 DOI: 10.1136/gut.2010.228023]

86 D’Avola D, Bilbao JL, Zozaya G, Pardo F, Rotellar F, Iñarriagaui M, Quiroga J, Sangro B, Herrero JL. Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. Transplant Proc 2012; 44: 2603-2605 [PMID: 23146469 DOI: 10.1016/j.transproceed.2012.09.050]

87 de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-768 [PMID: 20638742 DOI: 10.1016/j.jhep.2010.06.004]
